Cargando…
FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years
[Figure: see text]
Autores principales: | Shimony, Shai, Fell, Geoffrey, Chen, Evan C., Tsai, Harrison K., Wadleigh, Martha, Winer, Eric S., Garcia, Jacqueline S., Luskin, Marlise R., Stahl, Maximilian, Neuberg, Donna S., DeAngelo, Daniel J., Lindsley, R. Coleman, Stone, Richard M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509660/ https://www.ncbi.nlm.nih.gov/pubmed/37163357 http://dx.doi.org/10.1182/bloodadvances.2023009748 |
Ejemplares similares
-
Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials
por: Shimony, Shai, et al.
Publicado: (2023) -
Clinical Characteristics and Outcomes of Patients with Newly Diagnosed De Novo Acute Myeloid Leukemia (AML) during the COVID-19 Pandemic
por: Raman, Hari S., et al.
Publicado: (2021) -
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
por: Shimony, Shai, et al.
Publicado: (2022) -
getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019) -
Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)